Evaluation of Association between duration of Hospitalization in-Patient with Deep Venous Thrombosis and the type of Treatment Considering the Effect of Comorbid Diseases
Men's Health Journal,
Vol. 5 No. 1 (2021),
6 January 2021
Introduction: Deep vein thrombosis (DVT) is a common disease with serious risks such as pulmonary embolism and there are different anticoagulant therapies for treatment of this condition. In this study, we investigated the association between the duration of hospitalization with different treatment methods and comorbidities. Materials and methods: In this retrospective cross-sectional study, the hospital records of 213 patients with a diagnosis of acute DVT in Shohada-e-Tajrish Hospital in 2019 and 2020 were reviewed. Patients were divided into five main groups and five subgroups based on the type of treatment. Then, the association between the duration of hospitalization and different treatment methods was studied. Results: Treatment with novel oral anticoagulants (NOACs) with an average length of 2.5 days of hospitalization significantly reduces the duration of hospitalization. Combination therapy with low molecular weight heparin (LMWH) and warfarin or LMWH alone, with an average of 8.38 and 8.20 days, is preferable to treatment with unfractionated heparin (UFH) and warfarin, with an average of 9.2 days. Warfarin treatment with an average duration of hospitalization of 8.43 days is in the third place. The use of other methods has increased the duration of hospitalization. History of comorbidities including history of hospitalization, hypertension, smoking, cancer and trauma are the five comorbidities that have the greatest effect on the length of hospitalization of patients, respectively. Conclusion: According to the present study, treatment with NOACs reduces the duration of hospitalization of patients more than the other treatment methods. The second best choice is LMWH injection therapy and continuation with warfarin or starting and continuing treatment with LMWH preferable to injecting treatment with UFH and continuing with warfarin. The type of underlying disease and comorbidities had a significant effect on the duration of hospitalization.
- Deep vein thrombosis
How to Cite
2. Bartholomew JR. Update on the management of venous thromboembolism. Cleveland Clinic journal of medicine. 2017;84(12 Suppl 3):39-46.
3. Hansrani V, Khanbhai M, McCollum C. The diagnosis and management of early deep vein thrombosis. Thrombosis and Embolism: From Research to Clinical Practice. 2016:23-31.
4. Lee LH, Gallus A, Jindal R, Wang C, Wu C-C. Incidence of venous thromboembolism in Asian populations: a systematic review. Thrombosis and haemostasis. 2017;117(12):2243-60.
5. Bauersachs RM. Clinical presentation of deep vein thrombosis and pulmonary embolism. Best Practice & Research Clinical Haematology. 2012;25(3):243-51.
6. Jameson JL. Harrison's principles of internal medicine: McGraw-Hill Education; 2018.
7. Beyer-Westendorf J, Ageno W. Benefit–risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thrombosis and haemostasis. 2015;114(02):231-46.
8. Brien L. Anticoagulant Medications for the Prevention and Treatment of Thromboembolism. AACN advanced critical care. 2019;30(2):126-38.
9. Lang KJ, Saha P, Roberts LN, Arya R. Changing paradigms in the management of deep vein thrombosis. British journal of haematology. 2015;170(2):162-74.
10. Dang Y-P, Chen Y-F, Li Y-Q, Zhao L. Developments of anticoagulants and new agents with anti-coagulant effects in deep vein thrombosis. Mini reviews in medicinal chemistry. 2017;17(4):338-50.
11. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. Journal of Managed Care Pharmacy. 2007;13(6):475-86.
12. Minges KE, Bikdeli B, Wang Y, Attaran RR, Krumholz HM. National and regional trends in deep vein thrombosis hospitalization rates, discharge disposition, and outcomes for Medicare beneficiaries. The American journal of medicine. 2018;131(10):1200-8.
13. Morillo R, Jiménez D, Aibar MÁ, Mastroiacovo D, Wells PS, Sampériz Á, et al. DVT management and outcome trends, 2001 to 2014. Chest. 2016;150(2):374-83.
14. Pritchard ER, Murillo Jr JR, Putney D, Hobaugh EC. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Journal of Oncology Pharmacy Practice. 2019;25(1):52-9.
15. Isma N, Svensson PJ, Gottsäter A, Lindblad B. Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS). Thrombosis research. 2009;124(6):663-6.
- Abstract Viewed: 0 times
- pdf Downloaded: 0 times